Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for breast cancer and related endocrine-driven cancers. Its pipeline centers on palazestrant and OP-3136, with development and future commercialization intended in the United States and other key markets, either independently or with partners.

9.95

9.95

— Olema Pharmaceuticals, Inc.
%
Palazestrant55% Lead endocrine therapy candidate being developed for ER+ breast cancer in multiple settings.
OP-313625% KAT6 inhibitor program being evaluated for combination use in breast cancer.
Clinical development services15% Preclinical and clinical development activities supporting the pipeline.
Collaboration and partnering5% Research and development collaborations intended to expand development and commercialization reach.

Olema does not sell commercial products today; its near-term counterparties are clinical investigators, trial sites,...

  • Clinical trial sites and investigatorsprimary

    They run studies of palazestrant and OP-3136 and enable patient enrollment and data generation.

  • Pharmaceutical collaboration partnersprimary

    Partners such as Novartis and Pfizer collaborate on development and may support future commercialization.

  • Contract manufacturers and service providersprimary

    CMOs provide drug substance, drug product, labeling, and distribution for clinical supply.

  • Future oncology prescribers and treatment centersemerging

    If approved, oncologists and cancer centers would prescribe the therapies to patients with ER+ breast cancer.

Olema is headquartered in the United States and conducts its development activities through a global clinical and...

  • •Headquartered in the United States
  • •Clinical development and partnering extend beyond the U.S.
  • •Commercialization is intended in key global markets
  • •Third-party manufacturing may involve international supply chains
  • •Foreign regulatory and IP regimes affect future expansion

Olema’s strategy is to advance palazestrant in multiple ER+ breast cancer indications and to develop OP-3136 as a...

01
Advance palazestrant across ER+ breast cancer settingsshort-term

The lead asset is the main value driver and the foundation of the pipeline.

02
Develop OP-3136 in combination regimensmedium-term

A second clinical program can broaden the pipeline and create combination opportunities.

03
Build partnering and commercialization optionalitymedium-term

External partners can add development speed, market access, and commercial infrastructure.

04
Secure scalable manufacturing readinessmedium-term

Commercial approval would require reliable API, fill-finish, and packaging capacity.

Olema faces the core risks of a clinical-stage biotech: no approved products, dependence on successful trials and...

critical

No products approved for commercial sale

The company has no product revenue and must prove clinical and regulatory success before commercialization.

Scope
Entire business model
Materiality
high
high

Need for additional capital

Development-stage operations require ongoing funding for trials, manufacturing, and public-company costs.

Scope
Pipeline development and commercialization
Materiality
high
high

Clinical development and regulatory risk

Trial design, efficacy, safety, and approval decisions determine whether assets can advance.

Scope
Palazestrant and OP-3136
Materiality
high
high

Competitive intensity in oncology

Large pharma and biotech peers may develop similar or superior therapies faster.

Scope
ER+ breast cancer and endocrine-driven cancers
Materiality
high
high

Intellectual property protection

Value depends on protecting proprietary compounds and related uses across jurisdictions.

Scope
Palazestrant, OP-3136, future candidates
Materiality
high
medium

Third-party manufacturing dependence

The company relies on CMOs for clinical and future commercial supply, creating execution and quality risk.

Scope
API, drug product, labeling, distribution
Materiality
medium
Accrued research and development expenses
Can shift operating expenses between quarters
Stock-based compensation
Affects reported losses and diluted share count
Collaboration and milestone accounting
Can create volatility in reported revenue or other income if applicable
Clinical and manufacturing commitments
Affects liabilities and cash requirement disclosures

ELITE PHARMACEUTICALS INC /NV/

ELTP · Pharmaceutical Preparations

Oric Pharmaceuticals, Inc.

ORIC · Pharmaceutical Preparations

Processa Pharmaceuticals, Inc.

PCSA · Pharmaceutical Preparations

ATOSSA THERAPEUTICS, INC.

ATOS · Pharmaceutical Preparations

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

Erasca, Inc.

ERAS · Pharmaceutical Preparations

: 29/04/2026